Escaping the endosome: BEND lipids improve LNP mRNA delivery and gene editing
Every time a shuttle docks with the International Space Station (ISS), a delicate dance unfolds between the shuttle's docking ...
The Scientist4h
In a First, Mouse Pups with Two Dads Live to Adulthood
By using genetic material from two male mice, researchers successfully created pups that survived to adulthood, offering ...
This Company Is Trying To Bring The Woolly Mammoth And The Dodo Back To Life—A Biologist Explains
Colossal Biosciences is now valued at over $10 billion and is working on ambitious projects to resurrect multiple long ...
Genetic Swiss Army Knife: New Tool For Gene Editing And Therapy
This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...
Morgan Stanley Sticks to Their Buy Rating for Crispr Therapeutics AG (CRSP)
In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...
CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers
CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...
Psychology Today9d
Is Your Amazing Idea Being Thought by Someone Else?
Simultaneous discoveries in art and science highlight humanity's shared creativity, problem-solving, and the ...
Vertex Down 13% in 6 Months: Buy, Sell or Hold the Stock?
Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy ...
Fintel on MSN1d
Morgan Stanley Downgrades Intellia Therapeutics (NTLA)
Fintel reports that on January 27, 2025, Morgan Stanley downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 449.14% ...